Analysts have been eager to weigh in on the Healthcare sector with new ratings on MannKind (MNKD) and Irhythm Technologies (IRTC).
MannKind (MNKD)
In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on MannKind, with a price target of $6.50. The company’s shares closed last Thursday at $5.61, close to its 52-week high of $6.19.
According to TipRanks.com, Livnat is a 5-star analyst with an average return of 17.5% and a 57.3% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Zynerba Pharmaceuticals, and Verrica Pharmaceuticals.
Currently, the analyst consensus on MannKind is a Strong Buy with an average price target of $7.00, representing a 16.5% upside. In a report issued on February 17, Oppenheimer also assigned a Buy rating to the stock with a $7.00 price target.
See today’s analyst top recommended stocks >>
Irhythm Technologies (IRTC)
Oppenheimer analyst Suraj Kalia maintained a Hold rating on Irhythm Technologies today. The company’s shares closed last Thursday at $147.73.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 10.4% and a 56.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Cardiovascular Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Irhythm Technologies with a $228.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IRTC:
